当前位置: X-MOL 学术Biorheology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension.
Biorheology ( IF 1.1 ) Pub Date : 2016-02-19 , DOI: 10.3233/bir-15062
Yali Wang 1 , Feng Hu 2 , Xiaoyan Mu 3 , Feng Wu 1 , Dechun Yang 1 , Guixiang Zheng 2 , Xiaoning Sun 2 , Kaizheng Gong 2 , Zhengang Zhang 2
Affiliation  

OBJECTIVES Drag-reducing polymers (DRPs) are blood-soluble macromolecules which may increase blood flow and reduce vascular resistance. The purpose of the present study was to observe the effect of DRPs on monocrotaline-induced pulmonary hypertension (PH) in the rat model. METHODS A total of 64 male Wistar rats were randomly divided into four groups: Group I (pulmonary hypertension model + DRP treatment); Group II (pulmonary hypertension model + saline treatment); Group III (control + DRP treatment); Group IV (control + saline treatment). After five weeks, comparisons were made of the following indices: survival rate, body weight, blood pressure, right ventricular systolic pressure, right ventricular hypertrophy, wall thickness of pulmonary arteries, the internal diameter of small pulmonary arteries, plasma IL-1β and IL-6. RESULTS The survival rate after 5 weeks varied significantly across all groups (P=0.013), but the survival rates of Groups I and II were not statistically significantly different. Administration of DRP (intravenous injection twice weekly) attenuated the PH-induced increase in right ventricular systolic pressure and suppressed the increases in right ventricular (RV) weight and the ratio of right ventricular weight to left ventricle plus septum weight (RV/LV + S). DRP treatment also significantly decreased the wall thickness of pulmonary arteries, augmented the internal diameter of small pulmonary arteries, and suppressed increases in the plasma levels of IL-1β and IL-6. CONCLUSIONS DRP treatment with intravenous injection effectively inhibited the development of monocrotaline-induced pulmonary hypertension in the rat model. DRPs may have potential application for the treatment of pulmonary hypertension.

中文翻译:

减阻聚合物在单芥子碱诱导的肺动脉高压大鼠模型中的保护作用。

目的减阻聚合物(DRP)是可溶于血液的大分子,可增加血流量并降低血管阻力。本研究的目的是在大鼠模型中观察DRPs对单克crocroline诱发的肺动脉高压(PH)的影响。方法将64只雄性Wistar大鼠随机分为四组:I组(肺动脉高压模型+ DRP治疗); I组(肺动脉高压模型+ DRP治疗)。第二组(肺动脉高压模型+生理盐水治疗);第三组(对照组+ DRP治疗);第四组(对照组+生理盐水治疗)。五周后,比较以下指标:生存率,体重,血压,右心室收缩压,右心室肥大,肺动脉壁厚度,小肺动脉内径,血浆IL-1β和IL -6。结果各组5周生存率差异均有统计学意义(P = 0.013),但I,II组生存率差异无统计学意义。给予DRP(每周两次静脉注射)可减轻PH引起的右心室收缩压增加,并抑制右心室(RV)重量的增加以及右心室重量与左心室重量加隔膜重量的比率(RV / LV + S )。DRP处理还显着降低了肺动脉壁的厚度,增加了小肺动脉的内径,并抑制了IL-1β和IL-6血浆水平的升高。结论静脉注射DRP治疗可有效抑制大鼠模型中一丁crocroline诱发的肺动脉高压的发展。
更新日期:2019-11-01
down
wechat
bug